A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

Inclusion Criteria:

1. Participant must be 18 to 65 years of age inclusive, at the time of signing theinformed consent.

2. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline,as assessed by the ILA using a validated 4-point photographic scale.

3. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline,as assessed by the SSA using a validated 4-point categorical scale.

4. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderateto severe GL at maximum contraction at Baseline or moderate to severe (Grade 2 or 3)LCL (Stage 2) at maximum contraction (Stage as assessed by the ILA using a 4-pointphotographic scale).

5. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderateto severe GL at maximum contraction at Baseline and moderate to severe (Grade 2 or

3. LCL (Stage 3) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).

6. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderateto severe GL maximum contraction at Baseline or moderate to severe (Grade 2 or 3)LCL (Stage 2) at maximum contraction as assessed by the SSA using a 4-pointphotographic scale.

7. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderateto severe GL maximum contraction at Baseline and moderate to severe (Grade 2 or 3)LCL (Stage 3) at maximum contraction, as assessed by the SSA using a 4-pointphotographic scale.

8. Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines (Stages 1 to 3) atBaseline, as assessed by the SLS.

9. Male and female participants (only female for Stage 1/Step 1). Contraceptive use bymen or women should be consistent with local regulations regarding the methods ofcontraception for those participating in clinical studies

10. Capable of giving signed informed consent includes compliance with the requirementsand restrictions listed in the informed consent form (ICF) and in this protocol.

11. Participant has both the time and the ability to complete the study and comply withstudy instructions.

12. Does not reside in an institution by administrative or court order.

13. Is not a sponsor employee or clinical research unit personnel directly affiliatedwith the study or is not an immediate family member. Immediate family is defined asa spouse, parent, child or sibling whether biological or legally adopted.

Exclusion Criteria:

1. An active infection or other skin problems in the upper face including the GL, FHL,and LCL area (e.g. acute acne lesions or ulcers).

2. A history of eyelid blepharoplasty or brow lift within the past 5 years

3. A history of facial nerve palsy.

4. Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, orthick sebaceous skin.

5. Any known medical condition that may put the participant at increased risk in regardto exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome,amyotrophic lateral sclerosis, etc.)

6. Has COVID-19 illness or a known positive SARS-CoV-2 test (Stage 1), or the presenceof any other condition (e.g. neuromuscular disorder or other disorder that couldinterfere with neuromuscular function)

7. Previous treatment with any BoNT serotype for Stage 1 / Step 1 or any recenttreatment (within the past 9 months prior to baseline) with any BoNT serotype forStage 1 / Step 2, Stage 1/Step 3, Stages 2 and 3. Participants treated in earlierStages/Steps of the study must not be included in any later Stages/Steps.

8. Any prior treatment with permanent fillers in the upper face including the GL, FHLand LCL area.

9. Any prior treatment with long lasting dermal fillers or any permanent procedures inthe upper face inclusion the GL area within the past 3 years and/or skinabrasions/resurfacing (whatever the interventional technic used) within the past 5years, or photo rejuvenation or skin/vascular laser intervention within the 12months prior to Baseline.

10. Any planned facial cosmetic surgery during the study.

11. Use of concomitant therapy which, in the investigator's opinion, would interferewith the evaluation of the safety or efficacy of the study intervention. Therapyconsidered necessary for the participant's welfare may be given at the discretion ofthe investigator.

12. Use of medications that affect neuromuscular transmission, such as curare-like nondepolarising agents, lincosamides, polymyxins, anticholinesterases, aminoglycosideantibiotics and systemic retinoids, within the past 30 days prior to Baseline.

13. Use of any experimental device within 30 days or use of any treatment with anexperimental drug within five times the documented terminal half-life of therespective drug or its metabolites or if the halflife is unknown within 30 daysprior to the start of the study (prior to Baseline) and during the conduct of thestudy.

14. Known positive for hepatitis B antigen, or hepatitis C virus antibody, or for humanimmunodeficiency virus (HIV) or a diagnosis of acquired immunodeficiency syndrome.

15. Clinically diagnosed significant anxiety disorder, or any other significantpsychiatric disorder (e.g. depression) that might interfere with the participant'sparticipation in the study

16. An inability to substantially lessen GL and/or horizontal forehead rhytids even byphysically spreading them apart as determined by the investigator.

17. Known allergy or hypersensitivity to BoNT or any excipients of IPN10200 orDusport/Azzalure, or allergy to cow's milk protein.

18. A history of drug or alcohol abuse

19. Pregnant women, nursing women, premenopausal women or women of childbearingpotential not willing to practice a highly effective form of contraception method

20. Male participants who are not vasectomized and who have female partners ofchildbearing potential and are not willing to use condoms with spermicide throughoutstudy participation.

21. Any uncontrolled systemic disease or other significant medical condition which wouldbe harmful for the participant to be entered into the study or continueparticipation.